MAXCYTE, INC. (MXCT): restructuring charge — MaxCyte cuts 15% workforce, raises 2024 core revenue growth guidance to 6-8%

MAXCYTE, INC.

Reduction of 21 positions (~15% of global workforce) approved December 4, 2024.
Pre-tax charges of ~$0.8M, primarily in Q4 2024; ~$0.3M cash expenditures.
Annualized cost savings of ~$5.8M expected from January 2025.
Raises full-year 2024 core revenue guidance to 6-8% growth vs 2023; affirms SPL revenue ~$6M.
Employee count expected to end 2024 at 116, down from 143 at end of 2023.

Key facts

Extracted from this filing and checked against the source text.

Restructurings & Charges SEC 8-K Item 2.05/2.06 confidence 0.9

MAXCYTE, INC. announced a restructuring with charges of approximately $0.8 million affecting global workforce (a reduction of approximately 15% of the Company’s workforce globally).

Type: restructuring
Charge: approximately $0.8 million
Affected area: global workforce
Headcount: a reduction of approximately 15% of the Company’s workforce globally

Exact text from the filing

engaged through third-party employer-of-record (EOR) arrangements. In connection with the Plan, the Company estimates that it will incur total pre-tax charges of approximately $0.8 million, consisting primarily of severance payments, employee benefits, and related costs. These charges include costs associated with directly employed personnel as well as

View on SEC.gov

3 restructurings & charges filed in the last 30 days. Browse all restructurings & charges →

MAXCYTE, INC. filing history →

Source: SEC EDGAR

accession 0001558370-24-016085

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.